The company sells its cosmetic brands domestically via B2C, doctor-led clinics, and B2B contract manufacturing.
MUMBAI, May 26 (The CONNECT)- Branded and generic pharmaceutical and cosmetic products maker Astonea Labs Limited Initial Public Offering (IPO) opens for subscription on May 27 and closes on May 29, 2025. The company will be listed on the SME platform of BSE.
The company sells its cosmetic brands domestically via B2C, doctor-led clinics, and B2B contract manufacturing.
With a diverse product portfolio, the company’s offerings fully comply with regulatory standards and are WHO-GMP certified. It has also completed a US-FDA inspection, paving the way for entry into regulated international markets.
For its IPO, the Company has fixed the price band of ₹128 – ₹135 per Equity Share of face value ₹10 each for its IPO. Aiming to raise ₹37.36 Crore, calculated at Upper Price Band. Investors can bid for a minimum of 1,000 equity shares, with bids accepted in multiples of 1,000 shares thereafter.
The offer consists of a fresh issue of up to 27,90,000 equity shares with no Offer for Sale of Equity Shares. The Issue includes a reservation of up to 1,44,000 equity shares for subscription by market makers.
- Anchor investors: Up to 7,90,000 Equity Shares
- Net QIB : Up to 5,30,000 Equity Shares
- NII: Up to 3,99,000 Equity Shares
- Retail : Up to 9,27,000 Equity Shares
- Listing on: SME platform of BSE
An amountof ₹1.29 crore from the Net Proceeds from the fresh issue will be used for expenses on registration in Bolivia, South America, ₹ 5.23 crore for Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, ₹ 4.95 crore for advertising, marketing and brand building, ₹ 0.68 crore for Investment in procuring hardware and software, ₹ 19.75 crore for Funding of working capital requirements, and the balance for general corporate purposes.
Astonea Labs Limited is driven by an experienced leadership team and supported by 217 professionals. Its 7,500 sq. mt. manufacturing facility in Chandigarh holds 12 international accreditations, positioning it for both global and domestic markets.
In FY 24, the company clocked a total revenue of ₹80.28 crores as against ₹30.17crores in FY 22, recording a CAGR of 63.34%.
One view Corporate Advisors Private Limited is the sole BRLM, and KFin Technologies Limited is the registrar to the Issue.
